Ex parte HERVE - Page 5




          Appeal No. 95-0055                                                          
          Application No. 07/985,354                                                  


          scope of this reference (see the Brief, page 7, penultimate                 
          paragraph).                                                                 
               Similarly, the examiner has failed to support his                      
          contention that appellant’s disclosure of "EPARCYLŽ" is an                  
          "admission that mixtures of chabazite and phillipsite [natural              
          zeolites]... are known biological activators" (Answer, page                 
          3).  The disclosure on page 9, lines 12-17, of the                          
          specification must be taken in context with the disclosure at               
          page 2, lines 6-7, that ZEOPORT B180 alone is a mixture of                  
          natural zeolites and is not known to be suitable as a                       
          biological activator (specification, page 4, lines 8-17, see                
          the brief, page 8, penultimate paragraph).  The "prior                      
          biological activator" EPARCYLŽ (specification, page 9) is a                 
          natural clay material (see Exhibit 1 attached to the amendment              
          dated Oct. 15, 1991, Paper No. 9, in parent Application No.                 
          07/492,713).  There is no evidence in this record that                      
          mixtures of chabazite and phillipsite were known biological                 
          activators or that EPARCYLŽ contains any vitreous material or               
          zeolites.                                                                   
               For the foregoing reasons, we determine that the                       
          examiner’s legal conclusion of obviousness is not supported by              
                                          5                                           





Page:  Previous  1  2  3  4  5  6  7  8  9  Next 

Last modified: November 3, 2007